NR-LAMP for detecting FeLV proviral DNA in feline blood: findings and limitations
International journal of molecular sciences · 2025
In plain language
This laboratory study evaluated a test called NR-LAMP for detecting FeLV DNA in 98 blood samples from 98 cats that had tested positive with a commercial rapid test. Compared with PCR, it detected 97.3% of positive samples and gave no positive results among negative samples, although it missed two PCR-positive samples. This is a preliminary, unreplicated evaluation in a selected group of cats; it does not independently establish accuracy for diagnosing infection. It also does not show that detecting FeLV DNA can identify lymphoma or leukemia caused by the virus.
Scientific detail
The study, published in 2025 in the International Journal of Molecular Sciences (doi: 10.3390/ijms262411793), evaluated an in vitro neutral red-based colorimetric loop-mediated isothermal amplification assay (NR-LAMP) for detecting FeLV proviral DNA in feline blood. The clinical evaluation used 98 blood samples from 98 cats selected after a positive commercial rapid diagnostic test for FeLV. Each plasmid dilution level was analyzed in triplicate. This was a preliminary, unreplicated evaluation in a selected diagnostic cohort, not an unselected screening population or a lymphoma or leukemia cohort.
Against conventional PCR, reported sensitivity was 97.3% and specificity was 100% in the evaluated clinical samples (evidence level C). These are estimates relative to PCR, not accuracy established through independent adjudication of infection status or for cancer diagnosis. NR-LAMP missed two PCR-positive samples, so the source's description of perfect agreement is not supported by its own results. Inconsistent reporting of the detection limit and agreement is also noted.
NR-LAMP showed no cross-reactivity with the tested FIV, FCoV, FCV, FPLV, and FHV materials (evidence level B). The methods describe recombinant plasmid positive controls and water negative controls. This in vitro analytical finding applies to the tested panel and does not establish universal specificity across all pathogens or feline genomic sequences. The authors acknowledge that sensitivity was not 100% and propose target sequence variation and primer design as possible explanations for false negatives (evidence level C); they did not experimentally demonstrate the cause. Proviral DNA extraction remains necessary.
The measured endpoint was molecular detection relative to PCR, not malignant transformation. The assay could potentially support ascertainment of FeLV DNA status in lymphoma and leukemia research, but the study reports no tumor diagnoses or lymphoma, leukemia, or oncogenesis outcomes. It does not establish tumor-associated infection, proviral insertion sites, oncogenic mechanisms, cancer risk prediction, or discrimination between malignant and nonmalignant disease. The conclusion that this validation cannot identify FeLV-driven lymphoma or leukemia is an inference about the scope of the data, not a measured oncologic outcome.
What we know
In this selected cohort of 98 rapid-test-positive cats, NR-LAMP had reported sensitivity of 97.3% and specificity of 100% against conventional PCR, with two PCR-positive samples missed. No cross-reactivity was observed with the tested FIV, FCoV, FCV, FPLV, and FHV materials. The assay requires proviral DNA extraction. These findings come from a preliminary, unreplicated evaluation of molecular detection.
What we don't know
Accuracy against independently adjudicated infection status or in an unselected screening population has not been established. Neither the cause of false negatives nor universal specificity beyond the tested panel has been demonstrated. Inconsistent reporting of the detection limit and agreement limits their interpretation. This study does not establish whether FeLV DNA positivity identifies FeLV-driven lymphoma or leukemia; tumor-associated infection, proviral insertion sites, oncogenic mechanisms, cancer risk, and discrimination between malignant and nonmalignant disease were not evaluated.
Evidence
EvidenceLevel B — Direct experimental evidenceConfidence 100/100
NR-LAMP did not show cross-reactivity with the tested FIV, FCoV, FCV, FPLV, and FHV materials.
Excerpt verified in the source — verbatim, in the source's own language“The positive pink color of the NR-LAMP method developed here did not show cross-reactivity with FIV, FCoV, FCV, FPLV, and FHV, demonstrating high specificity for FeLV.”
This is FeLV-specific in vitro analytical evidence from an experiment for which Methods reports recombinant plasmid positive controls and water negative controls. It establishes the reported result for the tested panel, not universal specificity across all pathogens, feline genomic sequences, or FeLV variants. The Discussion explicitly names the negative cross-reactivity panel; the Results describes the same experiment less explicitly.
EvidenceLevel C — Preliminary evidenceConfidence 100/100
The authors propose target sequence variation and primer design as possible explanations for false-negative NR-LAMP results.
Excerpt verified in the source — verbatim, in the source's own language“Although our described method did not achieve 100% sensitivity, the occurrence of a false-negative outcome could be attributed to the DNA target’s sequence variation and self-designed primers.”
The evidence supports that the authors offered this explanation, not that they experimentally demonstrated the cause of the false negatives.
EvidenceLevel C — Preliminary evidenceConfidence 100/100
Against conventional PCR, NR-LAMP had reported sensitivity of 97.3% and specificity of 100% in the evaluated clinical samples.
Excerpt verified in the source — verbatim, in the source's own language“The sensitivity and specificity of LAMP were 97.3% (with 95% confidence intervals (CIs) of 91.8–99.5) and 100% (with 95% CIs of 84.1–99.8), respectively, when compared to conventional PCR.”
These are reported estimates relative to PCR in the selected cohort, not independently established accuracy for infection or cancer diagnosis. The source also reports two PCR-positive samples missed by NR-LAMP, so its description of perfect agreement is not supported by its own results. The specificity confidence interval is reproduced as printed, without correction.
EvidenceLevel C — Preliminary evidenceConfidence 100/100
The clinical evaluation used 98 blood samples from cats selected after a positive commercial rapid diagnostic test for FeLV.
Excerpt verified in the source — verbatim, in the source's own language“To implement the colorimetric LAMP assay in a clinical setting, we collected a random selection of 98 blood samples from cats (n = 98) that had tested positive for feline leukemia virus (FeLV) via a commercial rapid diagnostic kit.”
This describes a selected feline diagnostic cohort, not an unselected screening population or a lymphoma/leukemia cohort. The clinical validation is a preliminary, unreplicated evaluation.
InferenceConfidence 99/100
The reported assay validation does not establish whether FeLV DNA positivity identifies FeLV-driven lymphoma or leukemia.
The measured endpoint is molecular detection relative to PCR. Tumor diagnoses, tumor-specific proviral integration, and malignant outcomes are not reported, so an oncologic interpretation would require additional evidence.
AVA